Literature DB >> 15355596

Building protein interaction maps for Down's syndrome.

Katheleen Gardiner1, Muriel T Davisson, Linda S Crnic.   

Abstract

Now that the complete sequences for human chromosome 21 and the orthologous mouse genomic regions are known, reasonably complete, conserved, protein-coding gene catalogues are also available. The central issue now facing Down's syndrome researchers is the correlation of increased expression of specific, normal, chromosome 21 genes with the development of specific deficits in learning and memory. Because of the number of candidate genes involved, the number of alternative splice variants of individual genes and the number of pathways in which these genes function, a pathway analysis approach will be critical to success. Here, three examples, both gene specific and pathway related, that would benefit from pathway analysis are discussed: (1) the potential roles of eight chromosome 21 proteins in RNA processing pathways; (2) the chromosome 21 protein intersectin 1 and its domain composition, alternative splicing, protein interactions and functions; and (3) the interactions of ten chromosome 21 proteins with components of the mitogen-activated protein kinase and the calcineurin signalling pathways. A productive approach to developing gene-phenotype correlations in Down's syndrome will make use of known and predicted functions and interactions of chromosome 21 genes to predict pathways that may be perturbed by their increased levels of expression. Investigations may then be targeted in animal models to specific interactions, intermediate steps or end-points of such pathways and the downstream - perhaps amplified - consequences of gene dosage directly assessed. Once pathway perturbations have been identified, the potential for rational design of therapeutics becomes practical.

Entities:  

Mesh:

Year:  2004        PMID: 15355596     DOI: 10.1093/bfgp/3.2.142

Source DB:  PubMed          Journal:  Brief Funct Genomic Proteomic        ISSN: 1473-9550


  7 in total

Review 1.  The cognitive phenotype of Down syndrome: insights from intracellular network analysis.

Authors:  Avi Ma'ayan; Katheleen Gardiner; Ravi Iyengar
Journal:  NeuroRx       Date:  2006-07

2.  The proteins of human chromosome 21.

Authors:  Katheleen Gardiner; Alberto C S Costa
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-08-15       Impact factor: 3.908

3.  Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes.

Authors:  Mireia Vilardell; Axel Rasche; Anja Thormann; Elisabeth Maschke-Dutz; Luis A Pérez-Jurado; Hans Lehrach; Ralf Herwig
Journal:  BMC Genomics       Date:  2011-05-11       Impact factor: 3.969

4.  Sex differences in the proliferation of pulmonary artery endothelial cells: implications for plexiform arteriopathy.

Authors:  Shanshan Qin; Dan N Predescu; Monal Patel; Patrick Drazkowski; Balaji Ganesh; Sanda A Predescu
Journal:  J Cell Sci       Date:  2020-05-14       Impact factor: 5.285

Review 5.  Intersectin 1: a molecular linker in the central nervous system.

Authors:  Ning Ma; Rui-Fang Niu; Yong-Jie Ma
Journal:  Neurosci Bull       Date:  2008-12       Impact factor: 5.203

6.  Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801.

Authors:  A Siddiqui; T Lacroix; M R Stasko; J J Scott-McKean; A C S Costa; K J Gardiner
Journal:  Genes Brain Behav       Date:  2008-10       Impact factor: 3.449

7.  Understanding the basis for Down syndrome phenotypes.

Authors:  Randall J Roper; Roger H Reeves
Journal:  PLoS Genet       Date:  2006-03       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.